Triamterene: Target Organs and Levels of Evidence for TR-420
Toxicology and Carcinogenesis Studies of Triamterene (CASRN 396-01-0) in F344/N Rats and B6C3F1 Mice (Feed Studies)
Chemical (Study Title) CASRN | Peer Review Date | Route/Exposure Levels | Study Laboratory |
---|
Triamterene 396-01-0 | 11/21/1991 | Dosed-Feed R: 0,150,300,600, M: 0,100,200,400 PPM RESTART MICE: 0,400 PPM/50 PER GROUP | Battelle Columbus Laboratory |
Levels of Evidence
Male Rats: Equivocal Evidence
Type | Organ/Tissue (Lesion) |
---|
Neoplastic Lesions | - Liver:
ADENOMA 0/50 6/50 4/50 3/49
|
Non-Neoplastic Lesions | - LIVER: HYPERPLASIA; EOSINOPHILIC FOCI; MIXED CELL FOCI; INCREASED SEVERITY OF NEPHROPATHY
|
Female Rats: No Evidence
Type | Organ/Tissue (Lesion) |
---|
Non-Neoplastic Lesions | - LIVER: CLEAR CELL FOCI; MIXED CELL FOCI; INCREASED SEVERITY OF NEPHROPATHY
|
Male Mice: Some Evidence
Type | Organ/Tissue (Lesion) |
---|
Neoplastic Lesions | - Liver:
(FIRST STUDY) ADENOMA 17/50 22/50 19/50 20/60 OR CARCINOMA 5/50 7/50 3/50 13/60 COMBINED 20/50 26/50 19/50 29/60; (SECOND STUDY) ADENOMA 21/50 36/50 OR CARCINOMA 9/50 11/50 COMBINED 25/50 38/50
|
Non-Neoplastic Lesions | - THYROID GLAND: (FIRST STUDY) FOLLICULAR CELL HYPERPLASIA; (SECOND STUDY) FOLLICULAR CELL HYPERPLASIA
|
Female Mice: Some Evidence
Type | Organ/Tissue (Lesion) |
---|
Neoplastic Lesions | - Liver:
(FIRST STUDY) ADENOMA 10/50 22/50 23/50 36/60 OR CARCINOMA 4/50 4/50 3/50 8/60 COMBINED 13/50 26/50 25/50 37/60; (SECOND STUDY) ADENOMA 7/50 28/51 OR CARCINOMA 5/50 11/51 COMBINED 10/50 31/51
|
Non-Neoplastic Lesions | - LIVER: (FIRST STUDY) BASOPHILIC FOCI, CLEAR CELL FOCI; (SECOND STUDY) BASOPHILIC FOCI, CLEAR CELL FOCI
- THYROID GLAND: (FIRST STUDY) FOLLICULAR CELL HYPERPLASIA; (SECOND STUDY) FOLLICULAR CELL HYPERPLASIA
|